Ausgabe 1/2009
Inhalt (25 Artikel)
UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib
Judith Meza-Junco, Quincy S.-C. Chu, Olaf Christensen, Prabhu Rajagopalan, Soma Das, Ruslan Stefanyschyn, Michael B. Sawyer
Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines
Dhana E. Larsson, Sadia Hassan, Rolf Larsson, Kjell Öberg, Dan Granberg
PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin
Zhu Yuan, Fei Yan, Yong-sheng Wang, Huan-yi Liu, Lan-tu Gou, Xin-yu Zhao, Song-tao Lai, Hong-xin Deng, Jiong Li, Zhen-yu Ding, Shao-qun Xiong, Bing Kan, Yong-qiu Mao, Li-juan Chen, Yu-quan Wei, Xia Zhao
Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck
Byoung Chul Cho, Ki Chang Keum, Sang Joon Shin, Hye Jin Choi, Young Joo Lee, Se Hun Kim, Eun Chang Choi, Joo Hang Kim
A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors
Josephia R. Muindi, Candace S. Johnson, Donald L. Trump, Renee Christy, Kristie L. Engler, Marwan G. Fakih
ABT-737, a BH3 mimetic, induces glutathione depletion and oxidative stress
Adrienne N. Howard, Kathleen A. Bridges, Raymond E. Meyn, Joya Chandra
Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate
Punit H. Marathe, Amrita V. Kamath, Yueping Zhang, Celia D’Arienzo, Rajeev Bhide, Joseph Fargnoli
Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients
Barrie R. Cassileth, Naiyer Rizvi, Gary Deng, K. Simon Yeung, Andrew Vickers, Stacey Guillen, Derek Woo, Marci Coleton, Mark G. Kris
Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers
Afshin Dowlati, James Posey, Ramesh K. Ramanathan, Linda Rath, Pingfu Fu, Amitabh Chak, Smitha Krishnamurthi, Joanna Brell, Stephen Ingalls, Charles L. Hoppel, Percy Ivy, Scot C. Remick
A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer
Noboru Yamamoto, Tomohide Tamura, Takayasu Kurata, Nobuyuki Yamamoto, Ikuo Sekine, Hideo Kunitoh, Yuichiro Ohe, Nagahiro Saijo
Biological reactive intermediates that mediate dacarbazine cytotoxicity
Jalal Pourahmad, Marzieh Amirmostofian, Farzad Kobarfard, Jafar Shahraki
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors
Crystal S. Denlinger, Rebecca Blanchard, Lu Xu, Coen Bernaards, Samuel Litwin, Cynthia Spittle, Daniel J. Berg, Susan McLaughlin, Maryann Redlinger, Andrew Dorr, Julie Hambleton, Scott Holden, Anne Kearns, Sara Kenkare-Mitra, Bert Lum, Neal J. Meropol, Peter J. O’Dwyer
Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer
Muhammad Wasif Saif, K. I. Syrigos, S. Hotchkiss, J. Shanley, J. Grasso, T. M. Ferencz, K. Syrigos, M. M. Shah
A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer
Junji Furuse, Takuji Okusaka, Shinichi Ohkawa, Michitaka Nagase, Akihiro Funakoshi, Narikazu Boku, Kenji Yamao, Taketo Yamaguchi, Toshiya Sato
A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors
Zacharenia Saridaki, Periklis Pappas, John Souglakos, Martha Nikolaidou, Nikolaos Vardakis, Athanasios Kotsakis, Marios Marselos, Vassilis Georgoulias, Dimitris Mavroudis
Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours
Nobuyuki Yamamoto, Narikazu Boku, Hironobu Minami
Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors
Holly J. Meany, Katherine E. Warren, Elizabeth Fox, Diane E. Cole, Alberta A. Aikin, Frank M. Balis
The potential of vitamin K3 as an anticancer agent against breast cancer that acts via the mitochondria-related apoptotic pathway
Takeshi Akiyoshi, Sumio Matzno, Mika Sakai, Noboru Okamura, Kenji Matsuyama
A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucorvin for advanced biliary tract carcinoma
Jen-Shi Chen, Yee Chao, Tseng-Sheng Yang, Wen-Chi Chou, Li-Tzong Chen, Kuan-Der Lee, Yang-Chung Lin
Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer
Sung-Ji Lee, Sang-Hee Cho, Ju-Young Yoon, Jun-Eul Hwang, Woo-Kyun Bae, Hyun-Jeong Shim, Ik-Joo Chung
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies
Chia-Chi Lin, Muralidhar Beeram, Eric K. Rowinsky, Chris H. Takimoto, Chee M. Ng, Charles E. Geyer Jr, Louis J. Denis, Johann S. De Bono, Desiree Hao, Anthony W. Tolcher, Sun-Young Rha, Jacques Jolivet, Amita Patnaik
Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent
Amy W. Chun, Stephen C. Cosenza, David R. Taft, Manoj Maniar
Hepatic portal venous gas in a patient with metastatic non-small cell lung cancer on bevacizumab therapy: a case report and review of the literature
Jose Ortega, J. Michael Hayes, Scott Antonia
The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer
K. Dredge, J. A. Kink, R. M. Johnson, I. Bytheway, L. J. Marton
K-ras status in squamous cell anal carcinoma (SCC): it’s time for target-oriented treatment?
Maria Giulia Zampino, Elena Magni, Angelica Sonzogni, Giuseppe Renne